The Use and Safety of Cough and Cold Medications in the Pediatric Population

Area of Science:

• Pediatric Pharmacology
• Respiratory Medicine
• Evidence-Based Practice

Background:

• Viral respiratory illnesses are common in children, leading to frequent use of over-the-counter cough and cold medications (CCMs).
• Limited data exist on the safety and efficacy of CCMs in children under 6 years old.
• The U.S. Food and Drug Administration (FDA) advises against using antihistamine or decongestant products in children under 2 years.

Purpose of the Study:

• To review various cough and cold therapies for pediatric patients.
• To discuss the risks and benefits of different treatment options.
• To provide pharmacists with knowledge for making safe recommendations.

Main Methods:

• Literature review of pharmacologic and non-pharmacologic therapies for pediatric cough and cold symptoms.
• Analysis of safety and efficacy data for medications and complementary alternative medications (CAMs).
• Examination of current regulatory recommendations from bodies like the FDA.

Main Results:

• CCMs carry significant risks, including serious adverse events and potential mortality, especially when misused in pediatric populations.
• Evidence supporting the efficacy of CCMs in young children is scarce.
• Non-pharmacologic therapies and certain CAMs are also used, requiring careful consideration of their evidence base.

Conclusions:

• Pharmacists play a crucial role in guiding families on appropriate and safe treatment strategies for pediatric respiratory symptoms.
• Recommendations for CCM use in children under 6 years require careful evaluation due to safety concerns and limited efficacy data.
• A comprehensive understanding of all available therapies, including CAMs, is essential for optimal pediatric care.